Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 20, Issue 1, Pages 75-89Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.2015.1000299
Keywords
acute respiratory distress syndrome; inflammation; pharmacotherapy
Categories
Ask authors/readers for more resources
Introduction: Acute respiratory distress syndromes (ARDS) are devastating disorders of overwhelming pulmonary inflammation and hypoxemia, resulting in high morbidity and mortality. Areas covered: The main pharmacological treatment strategies have focused on the attempted inhibition of excessive inflammation or the manipulation of the resulting physiological derangement causing respiratory failure. Additionally, such interventions may allow reduced occurence mechanical ventilation injury. Despite promising preclinical and small clinical studies, almost all therapies have been shown to be unsuccessful in large-scale randomized controlled trials. The evidence for pharmacological treatment for ARDS is reviewed. Potential future treatments are also presented. Expert opinion: We suggest for future clinical trials addressing prevention and early intervention to attenuate lung injury and progression to respiratory failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available